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Abstract
Fibrosis is fundamental to the pathogenesis of many chronic lung diseases, including some lung infections, airway
diseases such as bronchiectasis and asthma, and most of the diffuse parenchymal lung diseases. Idiopathic
pulmonary fibrosis, the prototypical fibrotic lung disease, is amongst the most common diffuse parenchymal lung
diseases and is characterized by progressive decline in lung function and premature death from respiratory failure.
The clinical management of patients with this illness is hampered by our current inability to predict clinical
deterioration and lack of an effective therapy. Fibrocytes are a population of bone marrow-derived circulating
progenitor cells that home to injured tissues and differentiate into fibroblasts and myofibroblasts, thus contributing
to scar formation. We summarize the evidence supporting the role of these cells in the pathogenesis of fibrotic
lung diseases.
Fibrosis and lung disease
Fibrosis and tissue remodeling are critical components of
many diseases of the lungs. The most common categories
of lung disease, in order of frequency, are infections, air-
way diseases resulting from environmental exposures and
bronchogenic carcinoma. Tissue remodeling and deposi-
tion of extracellular matrix is detectable in all of these ill-
nesses and is fundamental to the pathogenesis of the first
two: Focal lung fibrosis is beneficial to the host in the
most common lung infections, namely infections caused
by mycobacteria and endemic fungi, by sequestering
microorganisms that cannot be eliminated by the host.
Fibrosis is also integral to development and progression
inflammatory airway diseases, including asthma, chronic
bronchitis and bronchiectasis, where histological develop-
ment of airway remodeling correlates with irreversible loss
of lung function. Deposition of extracelluar matrix is also
detectable in many cancers, although its relevance to
pathogenesis is less clear.
The archetypal fibrotic lung diseases are a less common
group of illnesses referred to as diffuse parenchymal lung
diseases – or less formally, as interstitial lung diseases.
This category encompasses a heterogeneous group of dis-
eases defined by chronic and multifocal inflammation and
fibrosis of the parenchyma, with involvement of alveolar,
interstitial and vascular spaces of the lungs. Diffuse par-
enchymal lung diseases include several fibrotic illnesses of
known cause: these are pathological responses to inhaled
inorganic dusts (pneumoconioses), hypersensitivity
responses to normally innocuous organic antigens (extrin-
sic allergic alveolitis or hypersensitivity pneumonitis), lung
fibrosis in the context of multi-system autoimmune dis-
eases (connective tissue disease-associated interstitial lung
diseases), and lung fibrosis as a response to drugs or radia-
tion. Diffuse parenchymal lung diseases also encompass a
large number of lung diseases of unknown cause – the lat-
ter group includes many well-defined clinical entities, such
as sarcoidosis; it also encompasses a group of illnesses,
referred to as idiopathic interstitial pneumonias, that have
historically been difficult to define clinically, and whose
identification necessitates the collaboration of expert
pulmonary physicians, radiologists and pathologists.
Idiopathic pulmonary fibrosis
The idiopathic interstitial pneumonias encompass several
histopathologic patterns, and include idiopathic pulmon-
ary fibrosis (IPF). IPF is the single most common of all
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disease in 2 respects: first, it is an illness characterized by
progressive fibrosis that culminates in death from
respiratory failure a median of 3 years after diagnosis
[1,2]; as such, it is the quintessential disease of pathologi-
cal fibrosis. Second, no treatment short of lung transplan-
tation has been shown to affect the natural history of IPF:
small studies that showed potential benefit for immuno-
suppressive regimens, in retrospect included patients that
had diffuse parenchymal lung diseases other than IPF
and were complicated by substantial drug toxicities;
meta-analyses do not support the use of corticosteroids
or non-steroid immunosuppressive agents in this disease
[3,4] and the utility of prednisone and azathioprine, a
commonly used regimen, was again disproved recently
[5]. Clinical trials of interferon gamma-1b, imatinib, eta-
nercept, sildenafil and bosentan have yielded negative
results [6-12]. The data regarding benefit of pirfenidone
is contradictory [12-16] leading to approval of its use in
Europe and Japan but not the United States; an expert
panel has recommended against its use based on the
observation that any beneficial effect of pirfenidone is
expected to be outweighed by significant adverse effects
[17]. The value of oral N-acetyl cysteine as monotherapy
has not been established and is under study [5]. A recent
study of an inhibitor of a tyrosine kinase downstream of
multiple growth factor receptors did not affect the pri-
mary outcome, decline in FVC, but showed a reduction
in incidence of acute exacerbation at the highest dose
tested, a potentially important finding if it is reproducible
[18]. In summary, due to its relative frequency and lack
of proven therapeutic options, there is a pressing clinical
need for new approaches to the management of IPF.
The lung histologic pattern in IPF is termed usual inter-
stitial pneumonia (UIP). The UIP histologic pattern is not
unique to IPF and also occurs in several diseases in which
the injurious agent is known, such as pneumoconioses,
chronic hypersensitivity pneumonitis and some cases of
the lung diseases due to connective tissue disorders. The
UIP pattern consists of normal areas of lung juxtaposed
with areas of leukocyte infiltration and other areas with
advanced fibrosis in a given low-power field [17,19]. This
variegated pattern has led to the hypothesis of temporal
heterogeneity. This hypothesis states that UIP is the con-
sequence of multiple episodes of inflammation and fibrosis
in response to multiple insults over time, and not the
response to a single insult [17]. Another histological fea-
ture of UIP is the presence of fibroblastic foci, areas of
polyclonal fibroblast and myofibroblast aggregation and
site of deposition of new collagen, thought to represent
areas of fibroblast proliferation and differentiation, and are
located at the edges of areas of dense fibrosis [17,20].
Given their pivotal role in the generation of the extracel-
lular matrix, fibroblasts and myofibroblasts are considered
the primary effector cells in the evolution of pulmonary
fibrosis, and their cellular source is thus a critical question
in the pathogenesis of fibrotic lung diseases. Currently,
3 hypotheses address the origin of lung fibroblasts [21-23]:
The classical concept is that tissue injury induces the
activation, proliferation and differentiation of a resident
fibroblast in the lung interstitial compartment into a myo-
fibroblast that migrates into the alveolar compartment and
expresses constituents of the extracellular matrix leading
to lung fibrosis. The second mechanism involves injury-
induced changes in the microenvironment of the epithe-
lium or endothelium, inducing their transition to a
mesenchymal phenotype and subsequently contributes to
fibroproliferation. The third mechanism pertains to a cir-
culating bone marrow-derived progenitor cell, the fibro-
cyte, that can home to sites of lung injury, differentiate
into fibroblasts and myofibroblasts, proliferate, and contri-
bute to the generation of extracellular matrix.
Relevance of fibrocytes to lung fibrosis in animal
models
Using the mouse model of intrapulmonary bleomycin
administration, CD45+ Col1+ CXCR4+ fibrocytes were
found to increase in the peripheral blood of animals chal-
lenged with intrapulmonary bleomycin as compared to
saline, and then return to steady state levels [24]. In con-
trast, lung fibrocytes began to appear in the lung 2 days
after bleomycin administration, peak at 8 days after bleo-
mycin and remained elevated between days 16 and 20; this
time course correlated temporally with deposition of col-
lagen in the lungs and suggested (but did not prove) mobi-
lization of fibrocytes from the bone marrow to the blood
and subsequently to the lungs. To address this issue defi-
nitively, several investigators have stable radiation chimeric
mice in which bone marrow cells express enhanced GFP
on the beta-actin promoter. These works have demon-
strated that in response to intra-pulmonary bleomycin or
lung irradiation, fibrocytes traffic and accumulate in the
lungs [25,26] and a subset differentiates into myelofibro-
blasts [27]. Consistent with this, when purified human
fibrocytes were intravenously transferred to SCID mice
that had been exposed to either bleomycin or saline,
greater numbers of human CD45+ Col1+ CXCR4+ fibro-
cytes were observed in bleomycin-challenged lungs as
compared to saline-treated controls [24].
In examining the chemokine receptor profile of circulat-
ing CD45+ Col1+ cells in mice, we have found that both
in normal mice and animals challenged with bleomycin,
CXCR4 is the most commonly expressed surface receptor,
being present in approximately 70% of the cells [27]. In
addition, CXCL12, the ligand for CXCR4, is expressed in
the lungs and is induced after intrapulmonary administra-
tion of bleomycin within one day and then remains ele-
vated for the subsequent 19 days; the dynamics of this
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CXCL12 in recruiting CXCR4+ fibroytes to the lungs.
Indeed, in vivo neutralization of CXCL12 resulted in
reduced number of lung CD45+ Col1+ CXCR4+ fibro-
cytes and a-SMA-expressing myofibroblasts as well as
reduced lung collagen content and attenuated pulmonary
fibrosis by histologic morphometric analysis, but did not
influence the number of lung neutrophils, macrophages,
CD4 and CD8 T cells or NK cells [24]. Consistent with
this, pharmacological antagonism of CXCR4 also results in
reduced lung fibrocyte numbers and pulmonary fibrosis in
response to bleomycin [28].
Work by other groups has examined the role of other
mechanisms in recruitment of fibrocytes to the lungs in
animal models of lung fibrosis. Using a model of intrapul-
monary fluorescein isothiocyanate-induced lung fibrosis,
fibrocytes were isolated from lung tissue and bronchoal-
veolar lavage after in vitro culture [29]. These cells
expressed CXCR4, CCR5, CCR7 and CCR2 and migrated
in response to CCL2 and CCL12 ligands. CCR2-deficient
mice treated with intratracheal FITC were found to have
lower levels of fibrocytes in the lung and less fibrosis as
compared to wildtype counterparts [30], and effect that
was later found to be independent of CCL2, but was
attributed to another CCR2 ligand, CCL12 [29]. CCR2 is
also highly expressed on cells of the mononuclear phago-
cyte lineage including monocyte, macrophage and dendri-
tic cell populations, however, and reduced lung fibrosis in
response to bleomycin in CCR2 knockout animals corre-
lated with a substantial reduction in these cells as well as
inflammatory cytokines in the bronchoalveolar lavage fluid
[31,32]; it is therefore not clear whether the observed
effect in CCR2-deficient animals is attributable to fibro-
cytes or other cell populations. Fibrocyte influx to the lung
in the bleomycin model has also been linked to the CCL3-
CCR5 chemokine axis; interestingly, this effect was asso-
ciated with reduced lung expression of lung CXCL12
expression in the lungs of CCL3- and CCR5-deficient ani-
mals, suggesting that the effect of CCL3-CCR5 may be
mediated via the CXCL12-CXCR4 axis [33]. Finally, in a
model of pulmonary over-expression of TGF-b, the num-
ber of lung fibrocytes and the extent of lung fibrosis were
attenuated by deletion of semaphorin 7a (a cell surface
receptor that interacts with b1 integrin) in bone marrow-
derived cells [34].
Are fibrocytes and CXCL12/CXCR4 relevant to
human interstitial lung disease?
Mouse models of lung fibrosis are helpful in identifying
potential mechanisms of human disease and to test cau-
sal relationships, but differ from human diffuse parenchy-
mal lung diseases in a number of important ways:
Importantly, most animal models of lung fibrosis are
caused by a single discreet exposure to an injurious
agent, which results in acute lung injury and inflamma-
tion, followed by a fibrotic stage, which eventually
resolved in surviving animals. In contrast, human IPF
does not have an identifiable inciting event, is character-
ized by a relapsing and remitting course rather than a
monophasic progression, and is progressive rather than
resolving. In addition, lung fibrosis in mouse models of
lung fibrosis does not show histological evidence of tem-
poral heterogeneity or fibroblastic foci, the hallmarks of
human UIP. Consistent with this, there are marked dif-
ferences between mechanisms identified in the bleomy-
cin-induced mouse model of pulmonary fibrosis and
human disease [35].
Similar to mouse fibrocytes, CXCR4 is the most promi-
nently expressed chemokine receptor on fresh peripheral
blood human fibrocytes, being expressed by 85% of circu-
lating CD45+ Col1+ cells; by comparison, CCR2 and
CCR7 are expressed by approximately 50% and 10% of
human blood fibrocytes [27]. Both CCR2 and CXCR4
expressed by fibrocytes are functional because human
cells display in vitro chemotaxis towards the CXCR4
ligand, CXCL12 [27] and the CCR2 ligand CCL2 [36]. In
addition, the chemokine ligand, CXCL12, was found to
be extensively expressed in lung tissue from patients with
the histologically diagnosed interstitial lung disease as
detected by immunohistochemistry and ELISA, but not
in histologically normal lungs [37]. A similar increase in
plasma CXCL12 levels in patients with interstitial lung
disease, supporting the concept that there is a CXCL12
gradient between the bone marrow and the blood to
allow release of fibrocytes from the bone marrow in these
patients. Consistent with this, there was >5-fold higher
concentration of circulating CD45+ Col1+ fibrocytes in
unmanipulated peripheral blood of patients with intersti-
tial lung disease as compared to healthy controls,
approximately 10% of which express aSMA, suggesting
further differentiation to myofibroblast phenotype [37].
These findings have now been corroborated by 2 other
groups, showing expanded fibrocyte pool in the lungs
and blood of subjects with scleroderma-associated inter-
stitial lung disease, associated with increased CXCL12
expressions in the lungs [38,39]. In addition, fibrocytes
have been documented in lung biopsy specimens of sub-
jects with IPF, where their numbers was associated with
elevated plasma and bronchoalveolar fluid CXCL12 and
correlated with the number of fibroblastic foci [40].
Most recently the correlation of circulating fibrocytes to
prognosis of IPF patients was tested. The proportion of
circulating CD45+ Col1+ cells in the buffy coat was found
to be elevated in patients with stable IPF as compared to
healthy controlled, and greatly increased in subjects
experiencing exacerbations of IPF, in whom it returned to
baseline levels in survivors who recovered from the
exacerbation [41]. The ratio of circulating fibrocytes did
Mehrad and Strieter Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S22
http://www.fibrogenesis.com/content/5/S1/S22
Page 3 of 5not correlate with physiological parameters in IPF patients
but was a powerful predictor of survival: subjects with
<5% circulating fibrocytes has a median survival of 27
months as compared to subjects with >5% fibrocytes
whose median survival was 7.5 months [41].
Can fibrocyte CXCR4 expression be manipulated
therapeutically?
As noted above, CXCR4 is the predominant chemokine
receptor on human and mouse fibrocytes, and interrupting
the CXCR4-CXCL12 axis in mice results in attenuation of
fibrosis. Furthermore, both hypoxia and growth factors
result in increase CXCR4 mRNA, CXCR4 cell surface
expression, and chemotaxis to CXCL12 in human fibro-
cytes [27]. This augmentation can be abrogated by expos-
ing cultured human fibrocytes to the mTOR inhibitor
sirolimus in vitro [27]. In the in vivo setting, treatment of
bleomycin-challenged mice with sirolimus has been shown
to result in reduced absolute number of CXCR4+ fibro-
c y t e si nt h eb l o o da n dl u n g sb u td i dn o ti n f l u e n c et h e
basal numbers of fibrocytes in the peripheral blood or
lung in mice treated with saline instead of bleomycin.
Consistent with its effect on fibrocyte infiltration, siroli-
mus treatment resulted in an approximately 60% decrease
in lung collagen deposition [27]. This result is consistent
with a prior report of effectiveness of sirolimus in a rat
model of pulmonary fibrosis [42], but does not exclude
the possibility of effects of sirolimus that may be indepen-
dent of CXCR4 expression or, indeed, fibrocytes. Given
the limited therapeutic options and poor prognosis of
human IPF, lack of optimal animal models that recapitu-
late the human disease, biological plausibility of a potential
benefit for mTOR inhibition in this disease, and the clini-
cal availability of mTOR inhibitors, a case can be made to
test this drug in a pilot study in human IPF.
Conclusions
Human diffuse parenchymal lung diseases are a heteroge-
neous group of illnesses characterized by various degrees
of lung inflammation and fibrosis. Data from animal
models, clinical studies and in vitro experiments support
a role for bone marrow derived fibrocytes in the patho-
genesis of these conditions. This information may prove
useful in the management of these diseases in two ways:
first, circulating fibrocyte concentration may be a bio-
marker of disease activity and prognosis, and second,
fibrocyte biology represents a potential therapeutic target
in these diseases.
Acknowledgements
This article has been published as part of Fibrogenesis & Tissue Repair Volume
5 Supplement 1, 2012: Proceedings of Fibroproliferative disorders: from
biochemical analysis to targeted therapies. The full contents of the
supplement are available online at http://www.fibrogenesis.com/
supplements/5/S1.
Competing interests
The authors declare that they have no competing interests.
Published: 6 June 2012
References
1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR,
Offord KP: Prognostic significance of histopathologic subsets in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157:199-203.
2. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU: The prognostic
significance of the histologic pattern of interstitial pneumonia in
patients presenting with the clinical entity of cryptogenic fibrosing
alveolitis. Am J Respir Crit Care Med 2000, 162:2213-2217.
3. Davies HR, Richeldi L, Walters EH: Immunomodulatory agents for idiopathic
pulmonary fibrosis. Cochrane Database Syst Rev 2003, CD003134.
4. Richeldi L, Davies HR, Ferrara G, Franco F: Corticosteroids for idiopathic
pulmonary fibrosis. Cochrane Database Syst Rev 2003, CD002880.
5. Clinical Alert: Commonly Used Three-drug Regimen for Idiopathic
Pulmonary Fibrosis Found Harmful. , http://www.nlm.nih.gov/databases/
alerts/2011_nhlbi_ifp.html (accessed 10/27/11).
6. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR,
Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic
pulmonary fibrosis. N Engl J Med 2010, 363:620-628.
7. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib
treatment for idiopathic pulmonary fibrosis: Randomized placebo-
controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610.
8. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L,
Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al: Effect of interferon
gamma-1b on survival in patients with idiopathic pulmonary fibrosis
(INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet
2009, 374:222-228.
9. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M,
Utz JP, Khandker RK, McDermott L, Fatenejad S: Treatment of idiopathic
pulmonary fibrosis with etanercept: an exploratory, placebo-controlled
trial. Am J Respir Crit Care Med 2008, 178:948-955.
10. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA,
Stahler G, Leconte I, Roux S, Raghu G: BUILD-1: a randomized placebo-
controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir
Crit Care Med 2008, 177:75-81.
11. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE
Jr: A placebo-controlled trial of interferon gamma-1b in patients with
idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125-133.
12. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH,
D’Amico R, Richeldi L: Non-steroid agents for idiopathic pulmonary
fibrosis. Cochrane Database Syst Rev 2010, CD003134.
13. Collard HR: Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J
2010, 35:728-729.
14. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M,
Takahashi H, Nakata K, Sato A, et al: The clinical significance of 5% change
in vital capacity in patients with idiopathic pulmonary fibrosis: extended
analysis of the pirfenidone trial. Respir Res 2011, 12:93.
15. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S,
Itoh H, Ohi M, et al: Double-blind, placebo-controlled trial of pirfenidone
in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2005, 171:1040-1047.
16. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al: Pirfenidone in
patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised
trials. Lancet 2011, 377:1760-1769.
17. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV,
Cordier JF, Flaherty KR, Lasky JA, et al: An official ATS/ERS/JRS/ALAT
statement: idiopathic pulmonary fibrosis: evidence-based guidelines for
diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
18. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG,
Brown KK, Flaherty KR, Noble PW, Raghu G, et al: Efficacy of a tyrosine
kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011,
365:1079-1087.
Mehrad and Strieter Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S22
http://www.fibrogenesis.com/content/5/S1/S22
Page 4 of 519. Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance
of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
20. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK:
Fibroblast foci are not discrete sites of lung injury or repair: the
fibroblast reticulum. Am J Respir Crit Care Med 2006, 174:654-658.
21. Kalluri R: EMT: when epithelial cells decide to become mesenchymal-like
cells. J Clin Invest 2009, 119:1417-1419.
22. Marshall R, Bellingan G, Laurent G: The acute respiratory distress
syndrome: fibrosis in the fast lane. Thorax 1998, 53:815-817.
23. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y: The role
of intraalveolar fibrosis in the process of pulmonary structural
remodeling in patients with diffuse alveolar damage. Am J Pathol 1987,
126:171-182.
24. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA,
Keane MP, Strieter RM: Circulating fibrocytes traffic to the lungs in
response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114:438-446.
25. Epperly MW, Guo H, Gretton JE, Greenberger JS: Bone marrow origin of
myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol
2003, 29:213-224.
26. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH: Bone marrow-derived
progenitor cells in pulmonary fibrosis. J Clin Invest 2004, 113:243-252.
27. Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a
therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009,
41:1708-1718.
28. Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, Moon HS, Park SH:
Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on
bleomycin induced murine pulmonary fibrosis. Exp Mol Med 2010,
42:465-472.
29. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB: The role of
CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell
Mol Biol 2006, 35:175-181.
30. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C,
Wilke CA, Toews GB: CCR2-mediated recruitment of fibrocytes to the
alveolar space after fibrotic injury. Am J Pathol 2005, 166:675-684.
31. Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH: CC-
chemokine receptor 2 required for bleomycin-induced pulmonary
fibrosis. Cytokine 2003, 24:266-276.
32. Okuma T, Terasaki Y, Kaikita K, Kobayashi H, Kuziel WA, Kawasuji M,
Takeya M: C-C chemokine receptor 2 (CCR2) deficiency improves
bleomycin-induced pulmonary fibrosis by attenuation of both
macrophage infiltration and production of macrophage-derived matrix
metalloproteinases. J Pathol 2004, 204:594-604.
33. Ishida Y, Kimura A, Kondo T, Hayashi T, Ueno M, Takakura N, Matsushima K,
Mukaida N: Essential roles of the CC chemokine ligand 3-CC chemokine
receptor 5 axis in bleomycin-induced pulmonary fibrosis through
regulation of macrophage and fibrocyte infiltration. Am J Pathol 2007,
170:843-854.
34. Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, Homer R, Gulati M,
Siner J, Elias J, et al: Role of semaphorin 7a signaling in transforming
growth factor beta1-induced lung fibrosis and scleroderma-related
interstitial lung disease. Arthritis Rheum 2011, 63:2484-2494.
35. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M: The bleomycin animal
model: a useful tool to investigate treatment options for idiopathic
pulmonary fibrosis? Int J Biochem Cell Biol 2008, 40:362-382.
36. Ekert JE, Murray LA, Das AM, Sheng H, Giles-Komar J, Rycyzyn MA:
Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic
responses in human and murine cultured fibrocytes. Fibrogenesis Tissue
Repair 2011, 4:23.
37. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM:
Circulating peripheral blood fibrocytes in human fibrotic interstitial lung
disease. Biochem Biophys Res Commun 2007, 353:104-108.
38. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN,
Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, et al: Circulating
monocytes from systemic sclerosis patients with interstitial lung disease
show an enhanced profibrotic phenotype. Lab Invest 2010, 90:812-823.
39. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S,
Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S: Altered monocyte
and fibrocyte phenotype and function in scleroderma interstitial lung
disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis
Tissue Repair 2011, 4:15.
40. Andersson-Sjoland A, de Alba CG, Nihlberg K, Becerril C, Ramirez R, Pardo A,
Westergren-Thorsson G, Selman M: Fibrocytes are a potential source of
lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol
2008, 40:2129-2140.
41. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L,
Dobranowski J, Boylan C, et al: Circulating fibrocytes are an indicator of
poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2009, 179:588-594.
42. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ,
Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates
bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002,
19:1124-1127.
doi:10.1186/1755-1536-5-S1-S22
Cite this article as: Mehrad and Strieter: Fibrocytes and the
pathogenesis of diffuse parenchymal lung disease. Fibrogenesis & Tissue
Repair 2012 5(Suppl 1):S22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mehrad and Strieter Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S22
http://www.fibrogenesis.com/content/5/S1/S22
Page 5 of 5